If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
148
results.
Updated on
15/07/2026 [07:22:00]
Results 75 to 100 of 148
Absstract of: US20260193700A1
The invention describes a kit for detection of a target polynucleotide using a CRISPR effector system that comprises CAS9 from Francisella novicida, a synthetic sgRNA and a detection scheme based on binding and subsequent enzymatic cleavage of the target polynucleotide. The invention also describes a method for detection of a target polynucleotide using the kit. The kit can be applied to both pathogenic and non-pathogenic polynucleotides and can be used to distinguish polynucleotides different by a single mismatch without the need for sequencing. The kit can also be used for detection of COVID-19. The kit is economical, easy to assemble and provides a robust and rapid readout that can be appropriately adapted for point of care applications.
Absstract of: US20260193724A1
0000 A method for the detection of SARS-CoV-2 in a sample based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) of a target nucleic acid sequence. The RT-LAMP amplicons are detected by gold nanoparticles (AuNPs) functionalized with a probe specific for regions of the target sequence. Kits for the detection of SARS-CoV-2 in a sample are also provided wherein the kit comprises a reverse transcriptase, a polymerase, a primer set for reverse transcription loop-mediated isothermal amplification (RT-LAMP) of the target sequence in a SARS-CoV nucleic acid sequence and variants thereof, and a conjugated nanoparticle solution comprising gold, water, and a probe sequence that is at least 85% identical to SEQ ID No.: 1.
Absstract of: WO2026148343A1
Compositions and methods for protecting against a wide spectrum of viral and bacterial infections, including Covid-19, and for treating established infection and infectious inflammation are described. The composition includes a novel combination of vitamins, minerals, nutraceuticals, and phytochemicals, which may be compounded as a pill, tablet, powder, capsule or liquid to be taken orally or via other administration routs one or more times per day, to serve as immune boosters, antibacterial agents, and antiviral agents along with providing anti-inflammatory effects in humans and animals.
Absstract of: WO2026148353A1
Provided are methods of suppressing an anti-oncolytic virus (anti-OV) antibody response to an oncolytic virus (OV) therapy. The methods comprise administering a B cell-depleting agent to a subject (e.g., a human subject) prior to and/or concurrently with administration of a therapeutic OV to the subject. Non-limiting examples of B cell-depleting agents include those that target CD19 or CD20. In some instances, a B cell-depleting agent comprises or consists of an antibody. In certain embodiments, the therapeutic OV administered to the subject is from the family Poxviridae, Herpesviridae, Adenoviridae, Paramyxoviridae, Rhabdoviridae, Reoviridae, Picornaviridae, Parvoviridae, or Coronaviridae. According to some embodiments, the B cell-depleting agent is administered (e.g., only administered) prior to and/or concurrently with an initial administration of the therapeutic OV to the subject. OV therapies of interest include, but are not limited to, OV cancer therapies.
Absstract of: WO2026147882A1
The present invention is generally directed to a potent therapy for SARS-CoV-2 (CoV2) disease using pharmaceutical composition disclosed herein. Provided a new combinatorial drag or a new pharmaceutical composition comprising compound of Formula (II-I-W-B), and their use for the treatment or prevention of coronavirus infections, particularly the use for the treatment or prevention of infections caused by SARS-CoV-2 and mutants thereof.
Absstract of: US20260193343A1
The present invention relates to an antiviral composition comprising Natural Killer (NK) cells as an active ingredient and, more particularly, to a composition for preventing or treating COVID-19 virus (SARS-COV-2) infection comprising NK cells as an active ingredient and a method for culturing lymphocytes comprising anti-COVID-19 virus NK cells.
Absstract of: US20260196317A1
A system and method that enables users to provide authenticated medical records (e.g., vaccination records, viral anti-body test results, etc.) to a third-party (e.g., a venue) to gain access to the third-party is provided. In this way, the third party may confirm that the user is sufficiently immune to a particular disease (e.g., COVID-19) and may thereby minimize the threat of the user introducing the contagious disease to the third party. The system includes a biometric data recognition system that authenticates the identity of a user, a medical records acquisition system that acquires the medical records of the authenticated user, and a system for the displaying or otherwise providing the medical records to the third-party for review. The system also includes a system identification card that includes the user's contact information, alphanumeric characters associated with the user's driver's license number, medical records of the user, and other elements.
Absstract of: US20260193327A1
0000 The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of antibodies.
Absstract of: EP4772515A1
The present invention belongs to the field of pharmaceutical technology and relates to a salt of a cyclic carbonate nucleoside compound, its crystal forms, preparation methods, and applications. The salt of the cyclic carbonate nucleoside compound has the structure shown in Formula I. When Y is hydrobromic acid and n=1, the salt of this nucleoside compound exists as Crystal Form A or Crystal Form B. Crystal Form A has advantages such as good physical and chemical stability, good solid properties, good water solubility, low hygroscopicity, and high oral bioavailability. It can be used to prepare drugs for treating and/or alleviating related diseases caused by viruses (particularly novel coronavirus, feline infectious peritonitis virus, respiratory syncytial virus, porcine epidemic diarrhea virus, feline calicivirus, etc.).
Absstract of: EP3913069A1
0001 The invention relates to a diagnostic kit for multiple detection of 4 viruses of the Family Coronaviridae: HCoV, SARS-CoV, MERS-CoV and the SARS-CoV-2 viral strain that has caused a pandemic of the disease known as COVID-19. The kit uses a "One-Step" approach with quantitative gene amplification after backward transcription of the viral genome (rRT-PCR). 0002 In order to avoid potential false negatives, the invention contains a double control using Porcine Epidemic Diarrhoea Virus (PEDV -CoV) and Ribonuclease P (RNase P-RP).
Absstract of: WO2026141623A1
Provided is an antiviral drug that is effective against SARS-CoV-2. Provided are: a compound represented by formula (I) (in the formula, Ar and R are as defined in the specification); a salt thereof; a solvate of these; a prodrug of these; and an anti-SARS-CoV-2 drug comprising these.
Absstract of: US20260183385A1
0000 Provided are a vaccine composition for pan-COVID-19 comprising a consensus sequence of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants.
Absstract of: US20260185108A1
0000 Levels of expression of antibiotic resistance genes are increased up to six-fold by inserting a proteasome-targeting tag into transgenes expressed in eukaryotic cells. Various selectable marker proteins are combined with different destabilization domains, leading to up to 70% increase in transgene expression. The increase in expression varies highly depending on the engineered construct and the lines cells used. Increase in expression drives exosome loading of cargo proteins in some aspects. By increasing expression and by editing trafficking signals of cargo proteins, proteins that normally locate to the ER can be trafficked to exosomes. This disclosure discloses efficient exosome delivery of a wide variety of engineered proteins, including modified antigen proteins of SARS-CoV-2 and influenza, and other proteins such as a modified alpha galactosidase A, an extracellular domain of vascular endothelial growth factor fused to a constant region of a human immunoglobulin heavy chain, and modified trastuzumab heavy and light chains.
Absstract of: US20260183407A1
0000 The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLKI, CLK2, CLK3, CLK4, and HASPIN. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, and HASPIN, such that the one or more kinases is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the one or more kinases. The bifunctional compounds serve as therapeutics for the treatment of Alzheimer's disease, down syndrome, diabetes, an autoimmune disease, an inflammatory disorder (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer), a viral infection (e.g., SARS-COV-2 infection (e.g., COVID-19)), and other diseases.
Absstract of: WO2026138823A1
Provided are a coronavirus-targeting broad-spectrum binding-blocking protein and a use thereof. Specifically, provided is a novel coronavirus Spike protein (S protein)-targeting binding protein having ultra-high affinity, wherein the protein can bind to an RBD area of the S protein and can block binding of a novel coronavirus to an ACE2 receptor, thereby blocking the novel coronavirus from invading host cells. Also provided is a novel coronavirus S protein-targeting self-assembling trimeric protein having high affinity, wherein the protein exhibits broad-spectrum blocking protection activity against novel coronaviruses.
Absstract of: WO2026139703A1
The present invention relates to compounds for use in the treatment of a disease or condition caused by Zika virus, Dengue virus, West Nile virus, Chikungunya virus, O`nyong`nyong virus, Sindbis virus or SARS-CoV-2 virus.
Absstract of: WO2026142889A1
Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as coronavirus colds and as a therapy against COVID-19. ImmunoFolate has been shown to reduce the incidents of colds and flus. In one embodiment is a method of treating cancer comprising administration of ImmunoFolate. In another embodiment is a method of treatment inflammatory -based disease and disorders comprising administration of ImmunoFolate.
Absstract of: US20260183383A1
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein and/or engineered nucleocapsid protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display and nucleocapsid-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple SARS-CoV-2 variants.
Absstract of: US20260176302A1
The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of polypeptides.
Absstract of: AU2026204287A1
The present disclosure relates to proteins which bind to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. un u n
Absstract of: WO2026133815A1
This cell-based formulation contains SSEA-3-positive pluripotent stem cells derived from mesenchymal tissue of a living body or derived from cultured mesenchymal cells. This cell-based formulation is characterized in that the formulation is for administration to address diseases and/or post-acute sequelae caused by SARS-CoV-2 infection. The present invention makes it possible to provide a cell-based formulation that contains pluripotent stem cells and is used for treating and/or preventing SARS-CoV-2 infection-caused diseases such as pneumonia and pulmonary fibrosis and SARS-CoV-2 infection-caused post-acute sequelae such as olfactory dysfunctions.
Absstract of: AU2026204379A1
The present invention relates to novel methods comprising the administration of pentosan polysulfate for treating or preventing coronavirus infection and cytokine- associated toxicity, including cytokine toxicity resulting from aberrant activation of the immune system in coronavirus disease or infection, such as those from SARS-CoV-2. 5 un u n
Absstract of: WO2026133305A2
A nanobody-based point-of-care lateral flow immunoassay (LFA) for the rapid, cost-effective detection of SARS-CoV-2 and MERS-CoV proteins in biological samples is disclosed. The assay described herein uses nanobody-based binding agents that selectively capture and detect viral antigens, such as spike (S) proteins and receptor-binding domains (RBDs), with high sensitivity and specificity. The LFA utilizes a colorimetric readout visible to the naked eye, eliminating the need for specialized equipment. The assay supports single and multiplex detection formats, enabling simultaneous analysis of multiple viral analytes. The LFAs are stable under standard storage conditions and provide a practical solution for decentralized and scalable testing.
Absstract of: WO2026131760A1
The present invention relates notably to specific single-domain antibodies (sdAbs) targeting RNA-dependent RNA polymerase (RdRp) activity and their use in the prevention and/or treatment of a virus infection from Coronaviruses, and more particularly of SARS-CoV-2.
Nº publicación: WO2026132293A1 25/06/2026
Applicant:
UPPSALA UNIV PROJEKT AB [SE]
ATEA PHARMACEUTICALS INC [US]
UPPSALA UNIVERSITET PROJEKT AB
ATEA PHARMACEUTICALS, INC.
Absstract of: WO2026132293A1
Advantageous specific symmetric diaryl hydantoin compounds are provided that have surprising activity as protease inhibitors against the main protease of coronavirus (MPRO), and thus can be used to treat a host in need thereof with a coronavirus including the SARS CoV-2 virus or a seasonal coronavirus in a host.
BOPI
Electronic site
